New FDA-Approved Targeted Drug for Treatment-Resistant, ER Positive HER2 Negative Breast Cancer

Precision Oncology specialist, Alex Rolland, discusses a new, recently FDA-approved, targeted treatment for patients with treatment-resistant ER positive HER2 negative breast cancer. He explains the results of the study that resulted in this approval and the key takeaways that impact patients with this exciting new development. He is joined by Precision Oncology Advocate and CTOAM cofounder, Michelle Morand. They share the key takeaways that patients need to know about this new treatment – including next steps you can take to find out if it will work for you and how to access it. 00:00 Introduction 00:16 Alex’s Presentation: Exciting New Development For Targeted Drugs in Treatment-Resistant, Estrogen (ER) Positive HER2 Negative Breast Cancer 02:30 New treatment development 04:10 Results from the recent CAPItello-291 trial 05:00 An important note re: stratification 06:32 Explanation of statistics used in this trial 10:20 What tests a patient needs to determine if this treatment will work for them 13:00 Next steps patients can take to access this treatment Read more about the CAPItello-291 trial: https://www.nejm.org/doi/full/10.1056... If you’d like to identify the most effective treatment for your cancer, and how to access it as soon as possible (and through your current treatment team, for as little cost as possible), reach out to us and book a free 30-min consult using the link below 👇 Book a Free Session With Alex And His Precision Oncology Team: https://www.ctoam.com/free-strategy-s... Download CTOAM’S Free Ebook Here: https://www.ctoam.com/ebook/ Join our (free) "Cancer Just the Facts" online program! 👉 https://cancerjustthefacts.com/ Get hundreds of free resources on Precision Cancer Medicine and access to our weekly Zoom calls with cancer experts. - CTOAM is a worldwide, Canadian-based personalized cancer care and precision oncology service specializing in getting our client's rapid access to the best possible cancer treatment available for their form of cancer, while assisting their physicians in having the most current data from which to make confident treatment decisions on your behalf. We facilitate access to peer-reviewed, science-based precision diagnostics such as PET/CT scans, liquid biopsy (blood-based genetic tests) and detailed genetic panels. We use these leading diagnostic tools, combined with a thorough and personalized research review, as our team explores the most advanced scientific data available today to find the best options for you. Other ways to stay in touch with CTOAM: Facebook:   / cancertreatmentoptionsandmanagement   LinkedIn:   / ctoam   Twitter:   / ctoam   Blog: https://research.ctoam.com/ LinkedIn (Liquid Biopsy Labs):   / 13063544   LBL Twitter:   / liquidbiopsynow   Disclaimer: Please understand that these videos are meant for educational purposes only. These videos are not intended to diagnose or be used as treatment advice. Viewers are encouraged to speak with their doctor or healthcare professionals for medical advice and before making any changes to their healthcare based on this information. All statements made in this video regarding medical treatments and health conditions are sourced and have been approved by the U.S. Food and Drug Administration (FDA). Watching this video is not a substitute for professional medical advice or a diagnosis.